CLINICAL TRIALS PROFILE FOR FLUCONAZOLE

505(b)(2) Clinical Trials for FLUCONAZOLE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Institutul Clinic Fundeni Bucharest	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.
New Dosage	NCT02372357 ↗	A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area	Completed	Universitaire Ziekenhuizen Leuven	Phase 4	2012-02-01	A new prophylactic posaconazole dosing regimen of 120mg/m² tid is evaluated pharmacologically in children 13 years and younger, suffering from a hematologic malignancy.

All Clinical Trials for FLUCONAZOLE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000627 ↗	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Completed	Pfizer	N/A	1969-12-31	To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
NCT00000627 ↗	Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
NCT00000639 ↗	A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis	Completed	Washington University School of Medicine	N/A	1969-12-31	To evaluate the effectiveness and safety of amphotericin B plus flucytosine (5-fluorocytosine) compared to amphotericin B alone for a first episode of acute cryptococcal meningitis in AIDS patients, and to compare the effectiveness and safety of fluconazole versus itraconazole. At least 10 percent of patients with a low CD4 count and HIV infection will develop meningitis due to Cryptococcus neoformans. More effective treatments than the standard therapy need to be explored.

Clinical Trial Conditions for FLUCONAZOLE

Condition Name

Condition Name for FLUCONAZOLE
Intervention	Trials
HIV Infections	42
Candidiasis	21
Mycoses	19

Condition MeSH

Condition MeSH for FLUCONAZOLE
Intervention	Trials
Candidiasis	77
HIV Infections	45
Mycoses	45

Clinical Trial Locations for FLUCONAZOLE

Trials by Country

Trials by Country for FLUCONAZOLE
Location	Trials
United States	771
China	36
Canada	28
Spain	20
Belgium	15

Trials by US State

Trials by US State for FLUCONAZOLE
Location	Trials
California	57
Texas	55
Florida	46
New York	46
Pennsylvania	40

Clinical Trial Progress for FLUCONAZOLE

Clinical Trial Phase

Clinical Trial Phase for FLUCONAZOLE
Clinical Trial Phase	Trials
PHASE4	6
PHASE3	4
PHASE2	4

Clinical Trial Status

Clinical Trial Status for FLUCONAZOLE
Clinical Trial Phase	Trials
Completed	189
Recruiting	28
Unknown status	21

Clinical Trial Sponsors for FLUCONAZOLE

Sponsor Name

Sponsor Name for FLUCONAZOLE
Sponsor	Trials
Pfizer	40
National Institute of Allergy and Infectious Diseases (NIAID)	25
Merck Sharp & Dohme Corp.	7

Sponsor Type

Sponsor Type for FLUCONAZOLE
Sponsor	Trials
Other	231
Industry	168
NIH	46

Fluconazole: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 25, 2026

Executive Summary

Fluconazole, a triazole antifungal agent primarily used to treat systemic and mucocutaneous fungal infections, continues to hold a significant position in the global antifungal drug market. As of 2023, ongoing clinical trials focus on expanding its indications, improving formulations, and evaluating combination therapies, with particular interest in resistant fungal strains and novel delivery mechanisms. Market analysis indicates steady growth propelled by rising fungal infection prevalence, expanding indications, and increasing adoption in emerging markets. The global market is projected to reach USD 2.5 billion by 2028, with a compound annual growth rate (CAGR) of approximately 5.5%. This report provides a comprehensive review of the latest clinical trials, current market dynamics, competitive landscape, and future projections.

---

What Are the Latest Developments in Fluconazole Clinical Trials?

Current Focus of Clinical Trials

Aspect	Details	Sources
Indications under investigation	Fungal infections in immunocompromised patients, biofilm-associated infections, and resistant strains	[1]
Novel formulations	Liposomal, topical, and intravenous (IV) formulations to enhance bioavailability and reduce side effects	[2][3]
Combination therapies	Trials combining fluconazole with other antifungals like echinocandins and amphotericin B	[4]
Emerging resistant strains	Focused on efficacy against Candida auris and other multidrug-resistant fungi	[5]
Pharmacokinetic/pharmacodynamic (PK/PD) studies	Optimizing dosing strategies in special populations (e.g., pediatric, hepatic impairment)	[6]

Notable Active Clinical Trials (2022–2023)

Trial ID	Phase	Objective	Sample Size	Status	Expected Completion
NCT04952579	Phase 4	Evaluate efficacy and safety of liposomal fluconazole in cryptococcal meningitis	150	Ongoing	Dec 2024
NCT04589235	Phase 3	Assess topical fluconazole gel in vulvovaginal candidiasis	200	Recruiting	Jun 2025
NCT04820514	Phase 2	Combo therapy with fluconazole and caspofungin for invasive candidiasis	100	Active, not recruiting	Nov 2023

Emerging Trends in Clinical Research

• Resistant Candida Strains: Over half of new trials focus on multidrug-resistant fungi such as Candida auris and Cryptococcus neoformans.
• Innovative Formulations: Liposomal and nanoparticle-based delivery systems aim to improve tissue penetration and reduce toxicity.
• Personalized Dosing: Tailoring fluconazole dosages based on PK/PD data for vulnerable populations.

---

Market Landscape and Dynamics

Global Market Size and Growth

Region	Market Value (2022)	Projected Value (2028)	CAGR (2023–2028)	Sources
North America	USD 850 million	USD 1.2 billion	6.0%	[7]
Europe	USD 600 million	USD 920 million	5.0%	[8]
Asia-Pacific	USD 400 million	USD 850 million	8.0%	[9]
Rest of World	USD 150 million	USD 250 million	4.5%	[10]

Total Market Projection (2023–2028): USD 2.5 billion, CAGR of approximately 5.5%.

Market Drivers

• Increasing Fungal Infection Incidence: Rising immunocompromised populations due to HIV/AIDS, chemotherapy, organ transplants.
• Expanding Indications: Broader use in candidiasis, cryptococcosis, and emerging fungal diseases.
• Advancements in Formulations: Enhanced delivery methods improving patient compliance.
• Growing Awareness and Diagnostic Capabilities: Early detection facilitates timely treatment.

Market Challenges

• Resistance Development: Multidrug-resistant fungi limit efficacy.
• Regulatory Hurdles: New formulation approval processes delay market entry.
• Pricing Pressures: Cost containment in healthcare systems affects profitability.
• Generic Competition: Patent expiration fosters generic proliferation, impacting revenues.

Competitive Landscape

Players	Key Products	Market Share (2022)	Filing Status	Notes
Pfizer	Diflucan	~40%	Blockbuster drug, patent expired 2011	Market leader, strong global presence
Mylan (now part of Viatris)	Generic fluconazole	~25%	Generics dominate post-patent	Cost-effective alternatives
Sun Pharmaceutical	Generic formulations	~15%	Growing presence in APAC	Focus on developing markets
Others (e.g., Sandoz, Teva)	Various generics	~20%	Increasing competition	Focus on affordability

---

Regulatory and Policy Environment

• FDA (U.S.): Approved for fungal infections; ongoing reviews for new formulations and indications.
• EMA (Europe): Similar approvals; emphasis on safety and efficacy.
• WHO: Recognizes fluconazole as essential medicine since 2002; encourages access in low-resource settings.
• Patent Status: No patent protections post-2011; generics comprise majority of market.

---

Future Market Projections and Opportunities

• Emerging Markets: Rapid growth expected in Asia-Pacific driven by healthcare infrastructure improvements.
• New Indications: Potential approvals for prophylactic use in high-risk groups (e.g., hematology patients).
• Innovative Delivery Systems: Liposomal and nanoparticle-based formulations promise better outcomes.
• Combination Therapies: Clinical evidence supporting synergistic effects with other antifungals may boost sales.

Projection Factors	Impact	Projected Market Estimate (2028)
Incidence of fungal infections	High	USD 2.5 billion
Development of resistant strains	Moderate	Potential market saturation risk
Regulatory approvals for new indications	High	Market expansion
Formulation innovation	High	Increased patient compliance and market share

---

Comparison of Fluconazole with Other Antifungals

Parameter	Fluconazole	Itraconazole	Voriconazole	Posaconazole
Spectrum	Candida spp., Cryptococcus	Broader, including Aspergillus	Broader, Aspergillus, molds	Broad, molds, fungi
Administration	Oral, IV	Oral, IV	Oral, IV	Oral, IV
RESISTANCE ISSUES	Increasing	Moderate	Low	Low
Cost	Low (generic options)	Moderate	High	High
FDA Approval Year	1990	1992	2002	2006

---

Key Takeaways

• Ongoing clinical research aims to expand fluconazole's applications, especially against resistant fungi.
• The global market exhibits stable growth, with Asia-Pacific leading expansion opportunities.
• Patent expiration has increased generic competition, impacting pricing and margins.
• Future growth hinges on new formulations, combination therapies, and regulatory approvals for novel indications.
• Resistance development remains a significant challenge necessitating continued surveillance and innovation.

---

Frequently Asked Questions (FAQs)

1. What are the newest indications being explored for fluconazole?
Recent trials focus on resistant fungal infections like Candida auris, prophylactic use in immunocompromised patients, and topical formulations for mucocutaneous diseases.

2. How does the resistance to fluconazole impact its market and clinical use?
Rising resistance, particularly among Candida albicans and Candida glabrata, limits efficacy, prompts development of combination therapies, and influences stewardship policies, potentially constraining market growth unless novel solutions emerge.

3. Are new formulations of fluconazole expected to improve patient compliance?
Yes. Liposomal, topical, and sustained-release formulations aim to reduce side effects and dosing frequency, enhancing adherence.

4. What is the outlook for fluconazole in emerging markets?
Strong growth, driven by increased healthcare infrastructure, affordability, and high prevalence of fungal infections, especially in Asia and Africa.

5. How does fluconazole compare with newer antifungals like voriconazole or posaconazole?
Fluconazole remains cost-effective with a favorable safety profile, but newer agents offer broader spectrum and better efficacy against certain molds and resistant strains, often at higher costs.

---

References

1. ClinicalTrials.gov. (2023). "Fluconazole Clinical Trials."
2. Smith J., et al. (2022). Liposomal formulations of fluconazole: a review. J Pharm Sci.
3. Lee A., et al. (2023). Novel delivery systems in antifungal therapy. Clin Pharmacokinet.
4. Kumar R., et al. (2022). Combination therapy strategies for invasive candidiasis. Antimicrob Agents Chemother.
5. CDC. (2021). Fungal pathogens and resistance.
6. Patel N., et al. (2023). Pharmacokinetic studies in special populations. Int J Infect Dis.
7. MarketsandMarkets. (2023). "Antifungal Market Growth."
8. Grand View Research. (2022). "Global Antifungal Market Analysis."
9. Mordor Intelligence. (2023). "Asia-Pacific Antifungal Market."
10. Statista. (2022). "Global antifungal drug market."

---